Ewa M. Davison, Ph.D.

Associate, Litigation  

Seattle 206.389.4564


Ewa Davison, Ph.D., focuses her practice on litigating patent matters and licensing disputes for companies in the life sciences, biotechnology, pharmaceutical and chemistry arenas. Ewa’s experience includes resolving disputes in the federal district courts and the Court of Appeals for the Federal Circuit, in addition to her inter partes review practice.

Ewa was accepted into the Federal Circuit Bar Association’s 2018–2019 Global Fellows Series, and will also be joining the Center for the Protection of Intellectual Property’s Thomas Edison Innovation Fellowship in 2019. She has also been repeatedly selected as a Washington “Rising Star” in the area of Intellectual Property Litigation.

Prior to joining Fenwick & West, Ewa clerked for the Honorable Richard C. Tallman of the Ninth Circuit Court of Appeals. She was previously an associate with Darby & Darby P.C. in Seattle.

Legal Publications

  • "A Cautiously Optimistic Diagnosis for Patent Eligibility at the Federal Circuit," Law360, May 2018 (co-author)
  • “State Universities and the Shifting Sans of Sovereign Immunity at the PTAB,” The Los Angeles Daily Journal, March 7, 2018
  • “Litigation Alert: Supreme Court Extends Petrella Rule Barring Laches to Patent Context,” Fenwick & West LLP, March 2017 (co-author)
  • “Biosimilars: Solicitor General Recommends Granting Certiorari in Amgen v. Sandoz,” Life Sciences Legal Insights Blog, December 2016 (co-author)
  • “Will the Supreme Court Review Whether FDA-Mandated Bioequivalence Testing to Maintain Approval Falls Within the § 271(e)(1) Safe Harbor?,” Life Sciences Legal Insights Blog, August 2016 (co-author)
  • “Federal Circuit: A Biosimilar Applicant Must Provide Notice of Intent to Market a Biosimilar Product, No Exceptions,” Life Sciences Legal Insights Blog, July 2016 (co-author)
  • “Litigation Alert: No Exception to Statutory Requirement that a Biosimilar Applicant Provide Notice of Intent to Market its Product,” Fenwick & West LLP, July 2016 (co-author)
  • “Federal Circuit clarifies the 'on-sale bar.' (The Medicines Co. v. Hospira, Inc.),” The Los Angeles Daily Journal, July 2016 (co-author)
  • “The Amgen Quagmire: Federal Circuit Rules Patent Dance Does Not Excuse Biosimilar Applicants from Providing Notice of Intent to Market,” IPWatchdog, July 2016 (co-author)
  • “Supreme Court Refuses to Put the Brakes on PTAB,” The Recorder, June 2016 (co-author)
  • “Biosimilars: Supreme Court Calls for Solicitor General’s Views in Amgen v. Sandoz,” Life Sciences Legal Insights Blog, June 2016 (co-author)
  • “Litigation Alert: Supreme Court Leaves Intact PTAB Authority to Institute and Regulate Inter Partes Review Proceedings,” Fenwick & West LLP, June 2016 (co-author)
  • “Biotech companies turn to ITC forum. (International Trade Commission),” The Los Angeles Daily Journal, April 2016 (co-author)
  • “Riddle Me This: The Federal Circuit Provides a Measure of Clarity to the Enigmatic Biosimilar Approval Pathway,” Fenwick & West LLP, August 11, 2015 (co-author)
  • “Murky Waters: Post-Approval Regulatory Activities and the § 271(e)(1) Safe Harbor,” Intellectual Property Bulletin, Winter 2013 (co-author)
  • “Final Patent Rules Provide Few Surprises,” Intellectual Property Bulletin, Summer 2012 (co-author)
  • “IP Litigation Alert: PTO Publishes Final Rules for Contested Patent Cases,” Fenwick & West LLP, August 2012 (co-author)
  • “Litigation Alert: Supreme Court Leaves Intact PTAB Authority To Institute And Regulate Inter Partes Review Proceedings,” Fenwick & West LLP, June 2012 (co-author)
  • “Supreme Court Allows Generic Manufacturers To Challenge Overbroad Use Codes,” Intellectual Property Bulletin, Spring 2012 (co-author)
  • “Patent Litigation Alert: Supreme Court Allows Generic Manufacturers to Challenge Overbroad Use Codes,” Fenwick & West LLP, April 2012 (co-author)
  • “California Supreme Court to Hear Cipro “Pay-for-Delay” Case,” February 2012 (co-author)
  • “The Dangers of the Digital Millennium Copyright Act: Much Ado About Nothing?,” Wm. & Mary L. Rev., 2008 (co-author)
  • “Biotech Patentees Can Navigate KSR,” Managing Intellectual Property, July/August 2008 (co-author)
  • “Enjoys Long Walks on the Beach: Washington’s Public Trust Doctrine and the Right of Pedestrian Passage over Private Tidelands,” Washington Law Review, 2006

Scientific Publications

  • “The LIN-15A and LIN-56 Transcriptional Regulators Interact to Negatively Regulate EGF/Ras Signaling in Caenorhabditis elegans Vulval Cell-Fate Determination,” Genetics, 2011 (co-author)
  • lin-8, which antagonizes C. elegans Ras-mediated vulval induction, encodes a novel nuclear protein that interacts with the LIN-35 Rb protein,” Genetics, 2005 (co-author)
  • “An ancient family of embryonically expressed mouse genes sharing a conserved protein motif with the T locus,” Nature Genetics, 1994 (co-author)

Legal Presentations

  • “Patent Eligibility in a Post Mayo World,” BIO IPCC, Spring 2018 (panel presentation)
  • “Patent Law Year in Review CLE,” Fenwick & West LLP, 2014 – 2016
  • “Toto, I’ve a Feeling We’re Not in Texas Anymore . . .,” BIO IPCC, Spring 2017 (panel presentation)
  • “Evolution or Devolution? Developments at the PTAB,” BIO IPCC, Spring 2016 (panel presentation)